Ultragenyx (RARE) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 42% year-over-year to $139–$139.5 million, driven by strong Crysvita, Dojolvi, and Evkeeza sales, and expanding global access across ~34 countries.

• Net loss for Q3 2024 was $133.5–$134 million ($1.40 per share), an improvement from Q3 2023, reflecting higher revenues and moderated expense growth.

• Advanced multiple late-stage clinical programs, including positive Phase 3 data for DTX401 (GSDIa), regulatory progress for UX111 (Sanfilippo syndrome), and FDA Breakthrough Therapy Designation for UX143 (osteogenesis imperfecta).

• Four approved products across five indications, with a robust rare disease pipeline and rapid development timelines.

• Ultragenyx completed a $381 million public offering in June 2024, further strengthening its balance sheet.

Financial highlights

• Q3 2024 total revenue reached $139–$139.5 million, up 42% year-over-year.

• Product contributions: Crysvita $98M, Dojolvi $21M, Evkeeza $11M, Mepsevii $10M.

• Operating expenses were $271–$271.5M (R&D $170M, SG&A $80M, cost of sales $21M), including $41.6–$42M in non-cash stock-based compensation.

• Net loss per share for Q3 2024 was $1.40, improved from $2.23 in Q3 2023.

• Cash, cash equivalents, and marketable securities totaled $824.7–$825M as of September 30, 2024.

Outlook and guidance

• 2024 total revenue guidance reaffirmed at $530M–$550M.

• Crysvita revenue expected toward the upper end of $375M–$400M; Dojolvi revenue projected at $75M–$80M.

• Net cash used in operations for 2024 anticipated to be around $400M.

• Path to GAAP profitability targeted by end of 2026, supported by product launches and PRV monetization.

• Key regulatory filings for UX111 and DTX401 planned around end of 2024 and mid-2025, respectively.